28 Jan 2025 • A study comparing metabolic surgery to nonsurgical treatment in patients with obesity and compensated metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis revealed promising long-term liver benefits.

Key Findings

• After a mean follow-up of 10 years, 15-year the cumulative incidence of major adverse liver outcomes (MALO) was significantly lower in the surgical group (20.9%) compared to controls (46.4%), with an adjusted hazard ratio of 0.28.
• Additionally, the incidence of decompensated cirrhosis was also reduced in the surgical group (15.6% vs. 30.7%, hazard ratio 0.20).

These findings suggest that metabolic surgery could be a safe and effective alternative to manage cirrhosis in patients with obesity and metabolic dysfunction-associated steatohepatitis.

Source: Nature | Read Full Story